The current evidence strongly supports the use of SGLT2 inhibitors for CKD patients with hyperfiltration-related conditions, including diabetes, obesity, advanced CKD or heart failure. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.